We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Telesis Bio Inc | NASDAQ:TBIO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.465 | 11.03% | 4.68 | 4.50 | 4.74 | 4.69 | 4.16 | 4.16 | 85,214 | 01:00:00 |
From May 2019 to May 2024
By Kim Richters
The French pharmaceutical major Sanofi SA said Friday that it is collaborating with Translate Bio Inc. to develop a new mRNA vaccine candidate against Covid-19.
The U.S. therapeutics company Translate Bio and Sanofi will research and develop "multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development," Sanofi said.
It is the second collaboration related to a new Covid-19 vaccine candidate for Sanofi after it in February started working with the Biomedical Advanced Research and Development Authority.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
March 27, 2020 02:53 ET (06:53 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Telesis Bio Chart |
1 Month Telesis Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
